Table 1.

Summary of Animals Included in This Study, Included Descriptions of Contusion Injuries, Transplant Injections, Recovery Periods, Tracing Procedures, and Terminal Electrophysiology

Group	N	Treatment	Immuno-suppression	PRV tracing	Additional tracing	Terminal electrophysiology
1	8	SD-FSC		PRV152 to TP	—	—
2	4	SD-FSC	—	—	BED to TP	PNR + antagonists
3	7	SD-FSC	—	PRV614 to diaph	—	diaph EMG
4	10	GFP-FSC	CSA	PRV614 to diaph	—	diaph EMG
5	6	GFP-FSC	CSA	PRV614 to diaph	BDA to C1/2	diaph EMG
6	7	HBSS	—	PRV152 to diaph	—	diaph EMG
7	5	HBSS	CSA	PRV614 to diaph	—	diaph EMG

After injury, all animals used in this study were divided into three treatment groups: vehicle injection (Hank's Balanced Salt Solution; HBSS), Sprague-Dawley derived FSC transplant (SD-FSC), or F344-GFP derived FSC transplant (GFP-FSC). Total number of animals per group (N) are as indicated. Animals receiving transgenic (GFP) FSC along with a subset of vehicle controls were immunosuppressed daily with CSA injections. Four weeks after transplant, animals were traced with pseudorabies virus (PRV), biotinylated dextran amine (BDA), or biotin ethylenediamnine (BED) applied to either the transplant (TP) or diaphragm (diaph). Terminal electrophysiology consisted of bilateral phrenic nerve recordings (PNR) or diaphragm electromyography (EMG).

Categories from left to right: Animal ID, injury impact force (kilodynes), impact displacement (ΔX; um), assisted ventilation required (yes or no), lesion description at the time of impact, initial weight loss within 1 week post-injury (wt loss, percent of pre-injury weight lost), days subcutaneous injections of fluids were required, days oral administration of Nutrical was required, number of cells injected into lesion cavity (in millions), whether there was visible reflex of cellular material at the time of withdrawal of the injection needle, the type of cells received (source of donor tissue being Sprague-Dawley [SD] or transgenic F344-EGFP-UBC [GFP]), additional weight loss within 1 week post-transplant (wt loss, percent of pre-transplant weight lost), days subcutaneous injections of fluids were required post-transplant, days oral administration of Nutrical was required post-transplant, type of PRV used in tracing procedures (RFP-expressing 614 or GFP-expressing 152), site of PRV administration (to diaphragm [diaph] or transplant [TP]), additional tracer injected in separate procedure (biotinylated ethylenediamine [BED] or biotinylated dextran amine [BDA]), site of additional tracer injection (TP or C1/2 ipsilateral gray matter), and terminal functional testing (phrenic nerve recording; PNR).

FSC, fetal spinal cord; GFP, green fluorescent protein.